drugset / Trial / NCT00143689
NRTI-Sparing Pilot Study
Phase 4
Completed
13 enrolled
University of British Columbia
Abbott · collabBoehringer Ingelheim · collabCIHR Canadian HIV Trials Network · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will compare a nucleoside reverse transcriptase inhibitor-sparing (NRTI-sparing) regimen (Kaletra + nevirapine) to two nucleoside reverse transcriptase inhibitor-based regimens (Combivir + nevirapine and Combivir + Kaletra). Participants will be randomly assigned to receive one of the following drug combinations: * lopinavir/ritonavir (Kaletra) and nevirapine (Viramune) twice a day; * Combivir (Zidovudine (AZT) plus lamivudine (3TC)) and nevirapine twice a day; * Combivir and lopinavir/ritonavir twice a day.
Timeline
- Start
- 2002-04
- Primary completion
- 2008-02
- Completion
- 2008-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lamivudine | Other / unclassified | — | — |
| Subject | Nevirapine | Small molecule | — | — |
| Subject | Zidovudine | Small molecule | — | — |
| Subject | lopinavir/ritonavir | Unknown | — | — |